Table 1 Demographic information and pathological characteristics of study participants and distribution of characteristics
| Â | n (%) |
|---|---|
Age at diagnosis | Â |
   ≤50 years | 133 (46) |
   >50 years | 158 (54) |
Race | Â |
   Caucasian | 239 (82) |
   African-American | 52 (18) |
Stage and node status | Â |
   Stage 1 | 82 (28) |
   Stage 2 negative | 57 (20) |
   Stage 2 positive | 87 (30) |
   Stage 3 | 48 (16) |
   Stage 4 | 17 (6) |
Estrogen receptor status | Â |
   Positive | 176 (64) |
   Negative | 101 (36) |
Progesterone receptor status | Â |
   Positive | 128 (46) |
   Negative | 148 (54) |
Treatment | Â |
   Chemotherapy only | 95 (33) |
   Radiation only | 25 (9) |
   Chemotherapy/radiation | 54 (19) |
   radiation/tamoxifen | 36 (12) |
   Chemotherapy/tamoxifen | 44 (16) |
   Chemotherapy/radiation/tamoxifen | 35 (12) |